Yuhan Corporation
000100
Rang in aandelen
#3833
Yuhan Corporation, a prominent South Korean pharmaceutical firm established in... Yuhan Corporation, a prominent South Korean pharmaceutical firm established in 1926 and headquartered in Seoul, specializes in the research, development, and manufacture of active pharmaceutical ingredients (APIs) and intermediates for both domestic and international markets. Its extensive product portfolio encompasses a wide array of prescription pharmaceuticals (ETC), addressing therapeutic areas such as cardiovascular, alimentary, genito-urinary, metabolic, respiratory, allergy, and neurological systems, alongside anti-infectives, anti-cancer treatments, and hormonal therapies. Notable offerings include Revanex, an acid pump antagonist designed for treating peptic ulcers and gastritis-related mucosal injury. Beyond prescription drugs, Yuhan Corporation provides a diverse range of over-the-counter (OTC) medications, including vitamins, mineral supplements, hepatopathy treatments, tonics, and drugs for respiratory, alimentary, dermatological, and pain relief applications. The company also extends its reach into consumer health and household goods, producing items like bleaches, detergents, pesticides, and oral care products. Further diversifying its operations, Yuhan is involved in the dental sector, supplying implants, equipment, consumables, and dental care solutions, and manufactures veterinary medical supplies for livestock, aquatic species, and companion animals. Additionally, it offers contract manufacturing services to other businesses.
Aandeelprijs
$63.22
Marktkapitalisatie
$4.27B
Verandering (1 dag)
-3.12%
Verandering (1 jaar)
-23.57%
Land
KR
Handel Yuhan Corporation (000100)
Categorie
Healthcare
Winst voor Yuhan Corporation (000100)
Winst in Jun 2026 TTM: $205.87M
Volgens de meest recente financiële verslagen van Yuhan Corporation bedraagt de huidige winst van het bedrijf $205.87M. In 2024 behaalde het bedrijf een winst van $41.79M, een daling ten opzichte van de winst van 2023, die $104.14M bedroeg. De weergegeven winst op deze pagina is de winst vóór rente en belastingen, oftewel EBIT.
Winstgeschiedenis van Yuhan Corporation van 2007 tot 2026
Winst aan het einde van elk jaar
| Jaar | Winst | Wijzigen |
|---|---|---|
| 2026 (TTM) | $205.87M | 33.56% |
| 2025 | $154.14M | 268.88% |
| 2024 | $41.79M | -59.88% |
| 2023 | $104.14M | 38.44% |
| 2022 | $75.22M | -29.06% |
| 2021 | $106.03M | -52.01% |
| 2020 | $220.97M | 364.61% |
| 2019 | $47.56M | -40.76% |
| 2018 | $80.28M | -40.96% |
| 2017 | $135.98M | -19.98% |
| 2016 | $169.93M | 18.62% |
| 2015 | $143.25M | 35.02% |
| 2014 | $106.09M | 4.27% |
| 2013 | $101.75M | 1.19% |
| 2012 | $100.55M | 9.06% |
| 2011 | $92.20M | -27.70% |
| 2010 | $127.53M | 8.26% |
| 2009 | $117.80M | 4.84% |
| 2008 | $112.36M | 0.30% |
| 2007 | $112.02M | 0.00% |
Winst van vergelijkbare bedrijven of concurrenten
| Bedrijf | Winst | Winstverschil | Land |
|---|---|---|---|
| $3.62B | 1,657.37% |
DE
|
|
| $3.40B | 1,553.97% |
DE
|
|
| $1.72B | 737.24% |
JP
|
|
| $930.30M | 351.89% |
CH
|
|
| $1.69B | 722.21% |
IN
|
